Introduction
============

In mitochondria, complex I (NADH:ubiquinone oxidoreductase) ([@B1]) uses potential energy from the oxidation of NADH by ubiquinone (Δ*E*) to translocate protons across the mitochondrial inner membrane, contributing to the proton-motive force (Δ*p*) that is used for ATP synthesis and transport processes. Complex I has an unusual L-shaped structure ([Fig. 1](#F1){ref-type="fig"}*A*); the redox reaction is contained in the hydrophilic domain that extends into the mitochondrial matrix, and proton translocation in the membrane-bound domain. Recent structural data from two prokaryotic complexes I ([@B2]) has revealed that the membrane-bound ND2, ND4, and ND5 subunits form three related structural units linked by a lateral helix from ND5; together they form the part of the membrane domain farthest from the hydrophilic domain. ND2, ND4, and ND5 are related to two subunits from the Mrp family of Na^+^/H^+^ antiporters ([@B3], [@B4]) (see [supplemental Fig. 1](http://www.jbc.org/cgi/content/full/M112.384560/DC1) and [Fig. 1](#F1){ref-type="fig"}*B*), suggesting that they share a common ancestor and that their mechanisms of ion translocation are related. Together, these observations suggest that, for energy transduction by complex I, redox-coupled conformational changes drive proton transfer through the three antiporter-like subunits.

![**Structural information about complex I, taken from 3M9S.pdb (*Thermus thermophilus* complex I), 3I9V.pdb (*T. thermophilus* hydrophilic domain), and 3RKO.pdb (six subunits of the *E. coli* hydrophobic domain) ([@B2], [@B57]).** *A*, complex I is an L-shaped enzyme, with a large hydrophilic domain containing the flavin mononucleotide, iron-sulfur (FeS) clusters, and the binding site for the ubiquinone headgroup. The membrane domain contains seven subunits; the structure of subunit ND1 has been determined only at low resolution, and two possible positions for helix I of ND3 are shown, from the low resolution structure of the intact enzyme and the *E. coli* membrane domain. The three helices absent from the mammalian ND2 subunit are shown in *black* ([@B51]), and the ends of the cysteine-containing loop of ND3, which is not resolved in the structure, are highlighted in *green* (the ends of ND3 helices I and II). The membrane domain is also shown from the top, with the hydrophilic domain removed, and labeled with the names of the *B. taurus* subunits. The antiporter-like subunits, ND2, ND4, and ND5, are indicated. *B*, the structure of *E. coli* NuoM (ND4; the 14 core helices of ND2 and ND5 have the same structure) ([@B2]). The transmembrane helices are in *light blue*; fully conserved residues between all of the antiporter-like subunits of *B. taurus* and *E. coli* and MrpA and MrpD from *B. subtilis* are shown in *purple* (see [supplemental Fig. 1](http://www.jbc.org/cgi/content/full/M112.384560/DC1)). Contact points with the lateral helix of ND5 are highlighted in *green*, and the loops in the two broken helices in *red*. On the *right*, the same structure is shown from the top.](zbc0401224110001){#F1}

Proton transfer is firmly established as the basis for energy conversion in mitochondria, but some bacteria use sodium ion transfer instead. For example, some organisms use Na^+^-coupled ATP synthases, and only minor adjustments to the residues of the ion-binding site are required to alter the specificity ([@B5]). Redox-driven Na^+^ translocation has been proposed also for complex I. The complexes I from *Klebsiella pneumoniae* ([@B6]) and *Escherichia coli* ([@B7]) have been proposed to be primary Na^+^ pumps (transport Na^+^ out of the cytoplasm), those from *Rhodothermus marinus* and *Escherichia coli* have been proposed to transport protons out of and Na^+^ into the cytoplasm together ([@B4], [@B8], [@B9]), and *E. coli* complex I has also been reported to be a simple H^+^-coupled enzyme ([@B10]).

Here, we use three preparations of tightly coupled membrane vesicles to define the ion translocation reactions of mitochondrial complex I (CI):[^2^](#FN3){ref-type="fn"} proteoliposomes (PLs) containing CI from *Bos taurus* (*Bt*) or the yeast *Yarrowia lipolytica* (*Yl*) and submitochondrial particles (SMPs) from *B. taurus* heart. PLs are simpler than SMPs because they contain only CI, but SMPs are more versatile because other respiratory enzymes can be used to set Δ*p* and reduce the quinone pool. In accord with the well established consensus, our results exclude the possibility of redox-driven sodium ion translocation by mitochondrial complex I. However, they reveal an additional ion transfer process in preparations containing the "deactive" form of *Bt*CI. In the absence of substrates, *Bt*CI converts slowly but spontaneously to a deactive form, which is readily reactivated by turnover (NADH:ubiquinone oxidoreduction) ([@B11], [@B12]). The "deactive transition" has been observed in SMPs, permeabilized mitochondria ([@B13]), cultured cells ([@B14]), and heart tissue ([@B15]), and it may be important during ischemia ([@B14]). Here, we show that the deactive form of *Bt*CI is a Na^+^/H^+^ antiporter. Our results provide new information about the mechanism of coupled ion translocation in complex I, and may be relevant to the role of complex I in ischemia-reperfusion injury.

EXPERIMENTAL PROCEDURES
=======================

### 

#### Preparation of CI, PLs, and SMPs

*Bt*CI and *Yl*CI were prepared as described previously ([@B16]--[@B19]) in 20 m[m]{.smallcaps} Tris-Cl (pH 7.4), 150 m[m]{.smallcaps} NaCl, 10% (v/v) ethylene glycol, 0.02% (w/v) *n*-dodecyl-β-[d]{.smallcaps}-maltoside (Anatrace), and 20 m[m]{.smallcaps} Na-MOPS (pH 7.2), 150 m[m]{.smallcaps} NaCl, 0.05% (w/v) *n*-dodecyl-β-[d]{.smallcaps}-maltoside, respectively. To prepare *Bt*PLs, a 1:2:1 (w/w) mixture of bovine heart phosphatidylcholine, phosphatidylethanolamine, and cardiolipin (Avanti Polar Lipids Inc.) in chloroform was dried under N~2~ and then homogenized to 10 mg ml^−1^ in 10 m[m]{.smallcaps} Tris-SO~4~, pH 7.5, 50 m[m]{.smallcaps} NaCl (unless otherwise stated) and extruded through a 0.1-μm Whatman Nuclepore track-etched membrane. The preformed liposomes were partially solubilized ([@B20]) using 1.2% *n*-octyl-β-[d]{.smallcaps}-glucoside (Anatrace), and the solution was sonicated to clarify it. Then, 0.15--0.25 mg ml^−1^ *Bt*CI (10--15 mg ml^−1^ stock solution) was added, the mixture was incubated for 10 min on ice, and prewashed SM-2 Bio-Beads (Bio-Rad) were added to remove the detergents ([@B21]) (50 μl of wet Bio-Beads per ml every 30 min for 4 h). The Bio-Beads were removed, and the *Bt*PLs were collected by centrifugation (70,000 × *g* for 30 min) and resuspended. *Yl*PLs were prepared similarly using soybean asolectin (Sigma-Aldrich) ([@B18]), with enzyme that had not undergone the final gel filtration step of the purification (this enzyme contains low levels of cytochrome *c* oxidase). Following reconstitution, the complex I in PLs was predominantly deactive ([@B11], [@B12]); when required, PLs (∼20 mg ml^−1^) were activated by incubating them on ice in 800 μ[m]{.smallcaps} NADH and 800 μ[m]{.smallcaps} decylubiquinone (DQ) for 10 min (until the NADH was consumed), and then the active PLs were collected by centrifugation, resuspended, and used immediately. For CI in PLs, the deactive status was confirmed by treating the PLs with 1 m[m]{.smallcaps} *N*-ethylmaleimide (NEM) for 25 min; following treatment, the deactive CI is catalytically inactive, whereas catalysis by the active CI is unaffected by the NEM ([@B22]).

*Bt*SMPs were prepared as described previously, in 10 m[m]{.smallcaps} Tris-SO~4~ (pH 7.5) and 250 m[m]{.smallcaps} sucrose ([@B23]), except the NADH incubation step was omitted. To deactivate the complex I, they were incubated at 37 °C for 20 min; to activate it, ∼10 mg ml^−1^ *Bt*SMPs were incubated in 1 m[m]{.smallcaps} NADH at 4 °C for 20 min and used immediately ([@B11], [@B12]). The active/deactive status of *Bt*SMPs was confirmed by measuring the reverse electron transfer activity; deactive *Bt*SMPs exhibit less than 10% of the reverse electron transfer activity of active *Bt*SMPs.

#### Spectroscopic Assays

Unless otherwise stated, SMP assays were in 10 m[m]{.smallcaps} Tris-SO~4~ (pH 7.5) and 250 m[m]{.smallcaps} sucrose, and PL assays were in 5 m[m]{.smallcaps} Tris-SO~4~ (pH 7.5) and 20 m[m]{.smallcaps} KCl, at 32 °C. NADH:O~2~ and NADH:DQ oxidoreduction were followed at 340--380 nm (ϵ~NADH~ = 4.81 m[m]{.smallcaps}^−1^ cm^−1^), and succinate:O~2~ oxidoreduction (in 20 m[m]{.smallcaps} succinate) was followed with a Clark electrode. Reverse electron transfer (succinate:NAD^+^ oxidoreduction driven by the Δ*p* from ATP hydrolysis) by SMPs was measured in 10 m[m]{.smallcaps} succinate, 1 m[m]{.smallcaps} NAD^+^, 1 m[m]{.smallcaps} ATP-MgSO~4~, and 400 μ[m]{.smallcaps} KCN ([@B23]). 10 μg ml^−1^ gramicidin (a mixture of A, B, C, and D, Sigma-Aldrich) or 25 μg ml^−1^ alamethicin (*Trichoderma viride*, Sigma-Aldrich) was used to dissipate Δ*p*. Complex I inhibitors ([@B24], [@B25]) were added at concentrations sufficient for \>95% inhibition of the NADH:O~2~ or NADH:DQ activity: 50 μ[m]{.smallcaps} capsaicin, 100 n[m]{.smallcaps} 2-decyl-4-quinazolinyl amine (from Dr. V. Zickermann, Frankfurt, Germany) ([@B26]), 30 μ[m]{.smallcaps} ethyl-isopropyl amiloride (EIPA) ([@B10], [@B27]--[@B29]), 150 n[m]{.smallcaps} fenpyroximate ([@B30]), 30 μ[m]{.smallcaps} Δlac-acetogenin (from Prof. H. Miyoshi, Kyoto, Japan, compound 7 in Ref. [@B31]), 5 m[m]{.smallcaps} 1-methyl-4-phenyl-pyridinium, 25 μ[m]{.smallcaps} palmitic acid ([@B32]), 1 μ[m]{.smallcaps} piericidin A, 200 μ[m]{.smallcaps} ranolazine ([@B33]), 200 n[m]{.smallcaps} rotenone, and 250 n[m]{.smallcaps} stigmatellin ([@B34]). To expose PLs and SMPs to NEM, they were incubated for 25 min on ice in 1 m[m]{.smallcaps} NEM (added from a 500 m[m]{.smallcaps} stock solution in DMSO) and then washed and collected by centrifugation and resuspended as above. Cytochrome *c* oxidase was inhibited by 400 μ[m]{.smallcaps} KCN.

The fluorescent dye 9-amino-6-chloro-2-methoxyacridine (ACMA, 0.25 μ[m]{.smallcaps}, Invitrogen Molecular Probes) was used to monitor ΔpH formation across the vesicular membranes (excitation at 419 nm, emission at 483 nm) ([@B23], [@B35]). In *Bt*SMPs, the Δ*p* from ATP hydrolysis was determined, with KCN to inhibit cytochrome *c* oxidase, by balancing the Δ*E* for NADH:fumarate oxidoreduction against Δ*p* ([@B23]).

#### Measurements of the Physical Properties of the Vesicles

"Oriented complex I" is complex I with its NADH-binding site exposed to the external solution; for PLs, the fractions of oriented complex I were determined from catalytic rates in the presence of gramicidin, measured in the presence and absence of 25 μg ml^−1^ *T. viride* alamethicin, a pore-forming antibiotic that allows NADH to enter the vesicular lumen ([@B36]). The hydrodynamic radii of the PLs and SMPs were determined by dynamic light scattering, using a Wyatt Technology Corp. DynaPro Titan or a Malvern Zetasizer Nano S, according to the Raleigh spheres model ([@B37]); each value is the average of three measurements, each consisting of 10 readings. The total internal volumes of the PL preparations were determined by including iron nitrate (10 μg liter^−1^ of iron, prepared from the Sigma-Aldrich iron AA/ICP calibration standard) in the reconstitution. The PLs were washed three times by centrifugation and resuspension in iron-free buffer, and then the total internal volumes were determined by measuring the iron contents ([@B19]) of matched pairs of samples prepared with and without additional iron.

RESULTS
=======

### 

#### Characterization of the PLs and SMPs

Comprehensive characterizations of the three preparations of coupled vesicles used here (*Bt*PLs, *Yl*PLs and *Bt*SMPs) are summarized in [Table 1](#T1){ref-type="table"}. Each preparation displays high catalytic activity (NADH:DQ oxidoreduction for PLs ([@B16], [@B38]) or NADH:O~2~ oxidoreduction for SMPs (involving complexes I, III, and IV of the respiratory chain, with endogenous ubiquinone-10 as an intermediate)) that is inhibited by piericidin A, a canonical complex I inhibitor. Gramicidin, an ionophore that collapses Δ*p*, stimulates catalysis significantly, showing that Δ*p* is substantial (see below also). Finally, average hydrodynamic radii and total internal volume measurements showed that each particle contains at least 100 correctly oriented enzyme molecules, allowing them to be treated as homogeneous populations.

###### 

**Characterization of the PL and SMP preparations**

The values reported in rows 1, 2, and 4 are in μmol NADH min^−1^ (mg of protein)^−1^. The respiratory control ratio (RCR, row 3) is a qualitative measure of how well the particles are coupled, but it depends also on the catalytic activity, the enzyme concentration in the membrane, and the ability of an enzyme to work against Δ*p*. In independent measurements on SMPs, ATP hydrolysis displayed an RCR value of only 1.6 but was shown to support a Δ*p* of more than 0.15 V ([@B23]). "Oriented complex I" is complex I with its NADH-binding site exposed to the external solution. The values reported in row 7 are in μmol NADH min^−1^ (mg of complex I)^−1^). Comparison of the values for *Bt*PLs and *Bt*SMPs shows that the CI in SMPs is around twice as active as that in PLs. However, the activity in *Bt*PLs is commensurate with values from the most active preparations of *Bt*CI ([@B16],[@B58]). The difference probably arises from the nonphysiological quinone analogue required for the *Bt*PLs and from the harsh procedure for preparing *Bt*PLs (solubilization and chromatography in detergent-containing solutions and reconstitution into an artificial membrane) relative to *Bt*SMPs (sonication and centrifugation steps that retain the native membrane). Our SMPs are comparable in size with those of Li *et al.* ([@B59]) (∼100 nm), and the value given for their total internal volume (in μl (mg of protein)^−1^) is a representative value based on that of Sorgato *et al.* ([@B60]) (1.3 μl (mg of protein)^−1^) and an equivalent value determined for this preparation using the same protocol (0.83 ± 0.12 μl (mg of protein)^−1^); the value is similar to values determined for inverted bacterial membrane vesicles using an EPR spin probe (1 μl (mg of protein)^−1^) ([@B8], [@B9]). The numbers of oriented complex I per particle are average values calculated from rows 5, 6, 8, and 9 by considering a uniform set of spherical particles, membrane thickness of 5 nm, and a uniform distribution of complex I.

                                          PLs           SMPs (*B. taurus*)   
  --------------------------------------- ------------- -------------------- ----------------------
  NADH:DQ or O~2~ oxidoreduction          0.90 ± 0.04   0.46 ± 0.03          0.25 ± 0.01 ([@B23])
  Row 1 with gramicidin                   2.39 ± 0.19   1.70 ± 0.04          0.74 ± 0.02 ([@B23])
  RCR value (row 2/row 1)                 2.66 ± 0.24   3.70 ± 0.26          3.02 ± 0.15
  Row 2 with piericidin A                 0.13 ± 0.03   0.055 ± 0.01         0.05 ± 0.02
  Fraction of oriented complex I          0.55 ± 0.03   0.48 ± 0.03          0.81 ± 0.05 ([@B23])
  Fraction of protein that is complex I   0.95 ± 0.01   ∼1                   ∼0.096 ([@B23])
  Row 2 corrected for rows 6 and 5        4.57 ± 0.48   3.54 ± 0.24          9.55 ± 0.70
  Particle radius (nm)                    143 ± 12      129 ± 4              163 ± 25
  Total internal volume                   22.8 ± 4.4    21.0 ± 6.2           ∼1.0
  Oriented complex I per particle         140           100                  700

#### Confirmation That Mitochondrial CI Catalyzes Only Redox-driven Proton Translocation

ACMA is a fluorescent dye that is used widely to demonstrate ΔpH formation across vesicular membranes; when ACMA is taken up by activated vesicles its fluorescence is quenched, most likely by dimerization and excimer formation ([@B39]). [Fig. 2](#F2){ref-type="fig"}*A* shows that adding NADH and DQ to *Bt*PLs, and NADH to *Bt*SMPs, rapidly quenches the ACMA fluorescence; the effect is reversed when ΔpH is dissipated by gramicidin or when proton translocation is inhibited by rotenone. Note that a membrane-permeant charge-compensating ion is required to dissipate Δψ (so that Δψ → 0 and ΔpH → Δ*p*). Thus, for *Bt*SMPs, chloride or nitrate was added to the external solution (the membrane is readily permeable to both ([@B23], [@B35], [@B40])), and for the PL experiment of [Fig. 2](#F2){ref-type="fig"}*A*, 25 m[m]{.smallcaps} K^+^ and valinomycin (a K^+^ uniporter) were present. The data in [Fig. 2](#F2){ref-type="fig"}*A* are fully consistent with redox-driven proton translocation by mitochondrial CI, but do not exclude additional ion translocation events. Two strategies, one kinetic and one thermodynamic, were used to investigate this possibility.

![**Mitochondrial complex I is a redox-coupled proton pump.** *A*, quenching of the ACMA fluorescence demonstrates ΔpH formation in *Bt*PLs and *Bt*SMPs. *Black*: *Bt*PLs (1.3 μg-protein ml^−1^), 200 μ[m]{.smallcaps} DQ, and 200 μ[m]{.smallcaps} NADH; 2 μg ml^−1^ gramicidin abolishes Δ*p*. Conditions are: 10 m[m]{.smallcaps} Tris-SO~4~, pH 7.5, 125 m[m]{.smallcaps} sucrose, 25 m[m]{.smallcaps} KCl, 2 μg ml^−1^ valinomycin, 20 °C. *Gray*: *Bt*SMPs (3.8 μg-protein ml^−1^), and 200 μ[m]{.smallcaps} NADH; 200 n[m]{.smallcaps} rotenone stops proton translocation, and Δ*p* dissipates. Conditions are: 10 m[m]{.smallcaps} Tris-SO~4~, pH 7.5, 125 m[m]{.smallcaps} sucrose, 80 m[m]{.smallcaps} KCl, 20 °C. *B*, the effect of Na^+^, K^+^ and Ch^+^ on the apparent Δ*p* (Δ*E*/2), generated by ATP hydrolysis by SMPs. The rate of NADH:fumarate oxidoreduction was recorded as a function of Δ*E*, where Δ*E* (V) = −0.315 − *RT*/2*F*.ln{(\[NADH\]\[fumarate\])/(\[NAD^+^\]\[succinate\])} using 0.1 m[m]{.smallcaps} \[NADH\], 1 m[m]{.smallcaps} \[NAD^+^\], 0.5 m[m]{.smallcaps} \[succinate\], 0.025--40 m[m]{.smallcaps} \[fumarate\]). When the net rate is zero, Δ*E*/2 = Δ*p* (assuming 4H^+^ per NADH). Conditions are: 10 m[m]{.smallcaps} Tris-SO~4~, pH 7.5, 32 °C, 0 to 100 m[m]{.smallcaps} MCl (*M*, Na^+^, K^+^, Ch^+^) with variable sucrose concentration (250 to 50 m[m]{.smallcaps}) to maintain the osmolarity. *Error bars* indicate S.D.](zbc0401224110002){#F2}

First, the rates of NADH:DQ oxidoreduction by *Bt*CI or *Yl*CI were measured as a function of the Na^+^, K^+^, and \[(CH~3~)~3~N(CH~2~)~2~OH\]^+^ (choline, Ch^+^) concentrations (0--100 m[m]{.smallcaps}); Ch^+^ is a monovalent cation that is clearly distinct from Na^+^ and K^+^. Some cation-dependent variation was evident (for *Bt*CI, Na^+^ stimulates the rate by up to 40% at intermediate concentrations, K^+^ stimulates less and at lower concentrations, and Ch^+^ does not stimulate at all, whereas for *Yl*CI, the effects of K^+^ and Na^+^ are more similar). However, the limited magnitude of these effects indicates a secondary effect, not tightly coupled Na^+^ or K^+^ translocation; we note that catalysis by *E. coli* complex I has a similar Na^+^ concentration dependence ([@B10]). Second, a "thermodynamic balance" experiment was used previously to quantify the Δ*p* produced by ATP hydrolysis in *Bt*SMPs ([@B23]); when the net rate of NADH:fumarate oxidoreduction (catalyzed by complexes I and II) is zero, the redox potential (Δ*E*) is balanced exactly by Δ*p* (at 2Δ*E* = 4Δ*p*, assuming the reaction has a 2e^−^ to 4H^+^ stoichiometry). Here, we asked whether there is a thermodynamic contribution from coupled Na^+^ or K^+^ transport that affects the point of balance. For example, if Na^+^ are co-translocated with the H^+^, then adding Na^+^ to the external solution would create a ΔNa^+^ that favors NADH oxidation over NAD^+^ reduction (an apparent uncoupling) and the apparent Δ*p* would decrease. [Fig. 2](#F2){ref-type="fig"}*B* shows that the external Na^+^, K^+^, or Ch^+^ concentration does not affect the apparent Δ*p* (the rate of ATP hydrolysis was not affected), so mitochondrial CI catalyzes only redox-coupled H^+^ transfer.

#### ACMA Fluorescence Experiments Indicate That Deactive BtCI Catalyzes Na^+^/H^+^ Exchange

In Experiment A ([Fig. 3](#F3){ref-type="fig"}), PLs loaded with Na^+^ (formed in high \[Na^+^\] buffer) were placed into low Na^+^ buffer (with the same pH and ionic strength, balanced with Ch^+^). If CI acts as an antiporter then Na^+^ from inside are exchanged for H^+^ from outside, and the intravesicular pH decreases (ΔNa^+^ is converted to ΔpH). It is not possible to control the Na^+^ concentration in the lumen of SMPs (see [supplemental Information](http://www.jbc.org/cgi/content/full/M112.384560/DC1)), so Experiment A is only possible for PLs. In Experiment B, SMPs were loaded with protons by succinate:O~2~ oxidoreduction (independently of CI) to drive proton uptake. Then, succinate oxidation was inhibited, and Na^+^ was added to the external solution. If CI acts as an antiporter, then H^+^ from inside are exchanged for Na^+^ from outside, and the intravesicular pH rises (ΔpH is converted to ΔNa^+^). It is not possible to load the lumen of PLs with sufficient H^+^ for this experiment without using CI itself, so Experiment B is only possible for SMPs. Ideally, both the intravesicular H^+^ and Na^+^ concentrations should be monitored during these experiments. However, despite extensive trials (see [supplemental Information](http://www.jbc.org/cgi/content/full/M112.384560/DC1)), we were unable to incorporate H^+^- and Na^+^-specific probes into the lumenal volumes of either PLs or SMPs while retaining the catalytic activity of CI. Therefore, we used ACMA to monitor the formation or dissipation of ΔpH (with Δψ collapsed to zero using a permeant ion).

![**Schematic representation of two experiments that reveal the Na^+^/H^+^ antiporter activity of complex I.** The diagrams represent a typical complex I PL (see data in [Table 1](#T1){ref-type="table"}); the complex at the top has been magnified. *A*, Na^+^-loaded vesicles are placed into a low \[Na^+^\] buffer. If complex I is a Na^+^/H^+^ antiporter, then Na^+^ efflux drives H^+^ uptake and the pH of the lumen rapidly decreases, forming ΔpH. *B*, the vesicles have been loaded with protons to create ΔpH. The driving force for H^+^ efflux is high, but uncatalyzed H^+^ efflux is slow; rapid H^+^ efflux is observed if it is coupled to Na^+^ uptake by complex I (the pH of the lumen rapidly increases, and ΔpH collapses).](zbc0401224110003){#F3}

During initial trials with *Bt*PLs and *Yl*PLs in Experiment A, and *Bt*SMPs in Experiment B, it was noted that the *Yl*PLs behaved more reproducibly than the *Bt*PLs or *Bt*SMPs; for *Bt*CI, different preparations presented very different levels of apparent antiporter activity. Subsequent investigation revealed that *Bt*CI, in both PLs and SMPs, was present as a mixture of deactive and active forms ([@B11], [@B12]), whereas *Yl*PLs were essentially all deactive (as judged by their NEM sensitivity) ([@B41]). Therefore, in all the experiments described below, the deactive/active status of each sample was defined as exactly as possible (see "Experimental Procedures").

[Fig. 4](#F4){ref-type="fig"}*A* shows how the fluorescence of ACMA responds when *Bt*PLs containing 50 m[m]{.smallcaps} NaCl are placed into buffer containing 5 m[m]{.smallcaps} NaCl and 45 m[m]{.smallcaps} ChCl. Deactive *Bt*PLs immediately quench the fluorescence, as Na^+^ efflux drives H^+^ uptake, creating ΔpH. Importantly, no significant quenching occurred with rotenone present or when the internal and external Na^+^ concentrations were equal. Furthermore, the effect of adding active *Bt*PLs was much slower and more limited than for deactive *Bt*PLs. In each case, monensin, a small-molecule Na^+^/H^+^ exchanger, takes the fluorescence to the same end-point level, as ΔNa^+^ and ΔpH equalize; the deactive *Bt*PLs have already reached this level. Finally, the pore-forming antibiotic alamethicin was added to dissipate both ΔNa^+^ and ΔpH; the fluorescence rapidly recovered its starting value. The results in [Fig. 4](#F4){ref-type="fig"}*A* suggest strongly that deactive *Bt*CI (but not active *Bt*CI) is a Na^+^/H^+^ antiporter that can be inhibited by rotenone. [Fig. 4](#F4){ref-type="fig"}*B* shows equivalent experiments using K^+^ instead of Na^+^, showing that the activity is specific to Na^+^.

![**Sodium ion efflux from PLs drives proton uptake by deactive *Bt*CI (Experiment A).** *A*, *Bt*PLs were prepared in 5 m[m]{.smallcaps} Tris-SO~4~, 50 m[m]{.smallcaps} NaCl, pH 7.4, and then placed into buffer containing 5 m[m]{.smallcaps} Tris-SO~4~, 5 m[m]{.smallcaps} NaCl, 45 m[m]{.smallcaps} ChCl, pH 7.4, and 0.25 μ[m]{.smallcaps} ACMA. Their active/deactive status (A- or D-form) was set beforehand (see "Experimental Procedures"). Each trace is the average from at least three experiments, with the standard deviations indicated by *shading*. 200 n[m]{.smallcaps} rotenone was included in the assay buffer as indicated, and 2 μg ml^−1^ monensin and 2 μg ml^−1^ alamethicin were added as indicated. The signal has been normalized to 100% when the *Bt*PLs were added and to 0% in the presence of monensin; ∼70% of the total fluorescence was quenchable. Note that the fluorescence is quenched slightly by the ethanol used for monensin and alamethicin. *B*, same as *A* except that the PLs contained 50 m[m]{.smallcaps} KCl and were placed into buffer containing 5 m[m]{.smallcaps} KCl and 45 m[m]{.smallcaps} ChCl. Conditions are: 21 °C, ∼20 μg ml^−1^ *Bt*CI.](zbc0401224110004){#F4}

For Experiment B ([Fig. 5](#F5){ref-type="fig"}*A*), succinate was added to *Bt*SMPs, to use succinate:O~2~ oxidoreduction to create ΔpH (the protons are translocated by complexes III and IV) and quench the ACMA fluorescence (Cl^−^, a permeant anion, ensures that Δψ is converted to ΔpH). Then, cyanide was added (to inhibit catalysis by complex IV and so stop proton translocation), along with 10 m[m]{.smallcaps} Na^+^ (ΔpH collapses when an antiporter is present as H^+^ efflux is coupled to Na^+^ uptake). For deactive *Bt*SMPs, the fluorescence recovers immediately (as ΔpH collapses); it recovers much more slowly in the presence of rotenone, or for active *Bt*SMPs. Note that deactive and active *Bt*SMPs exhibit the same respiratory control ratio for succinate:O~2~ oxidoreduction (1.6 ± 0.25), so the deactive particles are not uncoupled. In addition, when cycles of activation and deactivation were applied to *Bt*SMPs, the results from Experiment B alternated accordingly, although accompanied by a gradual loss of succinate:O~2~ oxidoreduction activity and/or coupling. [Fig. 5](#F5){ref-type="fig"}*B* shows equivalent experiments using K^+^ instead of Na^+^; the data are consistent with the antiporter activity being specific to Na^+^. Finally, the small apparent "burst" of recovery in [Fig. 5](#F5){ref-type="fig"}*A* upon the addition of Na^+^ and the "dip" in [Fig. 5](#F5){ref-type="fig"}*B* upon the addition of K^+^ are experiment-independent, ion-dependent artifacts of the ACMA system. In fact, otherwise identical experiments with Li^+^, Na^+^, K^+^, or Rb^+^ revealed an individual "signature" for each ion; we are currently unable to explain these effects.

![**Proton efflux from *Bt*SMPs drives sodium ion uptake by deactive *Bt*CI (Experiment B).** *A*, *Bt*SMPs were placed into buffer containing 10 m[m]{.smallcaps} Tris-SO~4~, 80 m[m]{.smallcaps} ChCl, 250 m[m]{.smallcaps} sucrose, pH 7.5, and 0.25 μ[m]{.smallcaps} ACMA. The active/deactive status of complex I (A- or D-form) was set beforehand (see "Experimental Procedures"). Each trace is the average from at least three experiments, with the standard deviations indicated by *shading*. 1 m[m]{.smallcaps} succinate, 5 m[m]{.smallcaps} Na~2~SO~4~, 0.5 m[m]{.smallcaps} KCN, and 2 μg ml^−1^ monensin were added as indicated. 200 n[m]{.smallcaps} rotenone was added along with the Na~2~SO~4~ and KCN where indicated. The signal has been normalized to 100% at the end of the experiment (to compare the traces during the recovery phase) and to 0% before the addition of M^+^ and cyanide (where M^+^ = Li^+^, Na^+^, K^+^, or Rb^+^); ∼60% of the total fluorescence was quenchable. *B*, same as *A* except with 5 m[m]{.smallcaps} K~2~SO~4~ instead of 5 m[m]{.smallcaps} Na~2~SO~4~. Conditions are: 21 °C, ∼30 μg ml^−1^ protein.](zbc0401224110005){#F5}

[Fig. 6](#F6){ref-type="fig"} shows a selection of results that have been quantified using the normalized fluorescence intensity 75 s after the PLs were added ([Fig. 4](#F4){ref-type="fig"}, Experiment A, expressed as the percentage of the normalized fluorescence that was quenched) or the time taken for the normalized fluorescence intensity to recover to 50% (*t*½) ([Fig. 5](#F5){ref-type="fig"}, Experiment B, expressed as 1/*t*½). In each case, high values indicate significant antiporter activity. [Fig. 6](#F6){ref-type="fig"}*A* shows the results from testing several complex I inhibitors in Experiment A (see "Experimental Procedures"). Capsaicin, the Δlac-acetogenin, 1-methyl-4-phenyl-pyridinium, piericidin A, ranolazine, and stigmatellin had no effect on the antiporter activity, whereas fenpyroximate (as well as rotenone) inhibited it. However, fenpyroximate was atypical because the slow initial rate of quenching eventually begins to increase; this was not observed for rotenone. EIPA is a canonical Na^+^/H^+^ antiporter inhibitor ([@B42]) that has been used to study proton translocation by complex I ([@B10], [@B27]--[@B29]), and palmitic acid has been linked to the deactive-active transition in complex I ([@B32]). Both inhibitors abolished ACMA fluorescence quenching by deactive *Bt*PLs, but no quenching was observed when monensin was added, and further investigation revealed that they are both uncouplers (see also Ref. [@B43]). It was not possible to identify any concentrations (from 5 p[m]{.smallcaps} to 5 m[m]{.smallcaps}) that inhibited but did not uncouple; EIPA and palmitic acid should not be used to study ion translocation by complex I. Similarly, 2-decyl-4-quinazolinyl amine is both a complex I inhibitor ([@B26]) and an uncoupler. In Experiment B, inhibition and uncoupling oppose each other, and inhibition of the antiporter activity by 2-decyl-4-quinazolinyl amine could be observed at low concentrations (100 n[m]{.smallcaps}).

![**Characteristics of the antiporter reactions in PLs and *Bt*SMPs.** *A*, *Bt*PLs, with deactive CI, were tested using Experiment A in the presence of various inhibitors. A high value for the normalized fluorescence quench (100% fluorescence quench = fluorescence in the presence of monensin) 75 s after the PLs were added indicates high antiporter activity ([Fig. 4](#F4){ref-type="fig"}). *Caps.*: 50 μ[m]{.smallcaps} capsaicin; *Fenp.*: 150 n[m]{.smallcaps} fenpyroximate; *Aceto.*: 30 μ[m]{.smallcaps} Δlac-acetogenin; *MPP^+^*, 5 m[m]{.smallcaps} 1-methyl-4-phenyl-pyridinium; *Pier.*: 1 μ[m]{.smallcaps} piericidin A; *Ranol.*: 200 μ[m]{.smallcaps} ranolazine; *Rot.*: 200 n[m]{.smallcaps} rotenone; *Stig.*: 250 n[m]{.smallcaps} stigmatellin. *NEM* indicates that the *Bt*PLs were preincubated in 1 m[m]{.smallcaps} NEM for 25 min and then washed and collected by centrifugation. *B*, *Bt*PLs and *Yl*PLs were tested using Experiment A following activation (*-A*) or deactivation (*-D*). *C*, *Bt*SMPs, with active or deactive CI, in the presence or absence of 200 n[m]{.smallcaps} rotenone (*Rot.*), were tested for M^+^/H^+^ antiporter activity (M^+^ = Li^+^, Na^+^, K^+^, or Rb^+^). A high 1/*t*½ (where *t*½ is the time taken for the fluorescence to recover to half its full value upon the addition of M^+^) indicates significant antiporter activity ([Fig. 5](#F5){ref-type="fig"}).](zbc0401224110006){#F6}

[Fig. 6](#F6){ref-type="fig"}*A* shows that treating deactive *Bt*PLs with NEM, as required to derivatize the widely conserved cysteine in ND3 that is accessible only in the deactive enzyme ([@B22]) ([Fig. 1](#F1){ref-type="fig"}*A*), inhibits the antiporter activity. Note that it was necessary to remove the NEM before the assay to avoid artifacts in the ACMA measurement; this extra experimental step, and the effects of small amounts of DMSO, resulted in greater variation in the results. Qualitatively similar results were obtained from SMPs, except that side reactions of NEM with complex II compromised the formation of ΔpH, decreasing the intensity of the ACMA response. In separate experiments, ATP hydrolysis was used to create ΔpH and inhibited by adenosine 5′-(β,γ-imido)triphosphate ([@B44]); ATP hydrolysis was also affected by NEM, but a large enough ΔpH could be formed to confirm that the antiporter activity of complex I is sensitive to NEM. [Fig. 6](#F6){ref-type="fig"}*B* shows that *Yl*PLs do not display any Na^+^/H^+^ antiporter activity, irrespective of attempts to convert the *Y. lipolytica* enzyme between the deactive and active forms. Finally, [Fig. 6](#F6){ref-type="fig"}*C* compares the results from Experiment B with Li^+^, Na^+^, K^+^, and Rb^+^, confirming that antiporter activity is Na^+^-specific.

#### Vesicle-swelling Experiments Confirm That Deactive BtCI Catalyzes Na^+^/H^+^ Exchange

Mitochondria-swelling experiments in isotonic media have been used to characterize ion movement across the inner mitochondrial membrane ([@B45]--[@B47]); ions accumulating in the matrix cause water uptake (both a cation and an anion must be taken up to balance the charge), and the mitochondria swell as the inner membrane unfolds. Here, we used an analogous approach to monitor ion uptake by *Bt*SMPs; changes in the hydrodynamic radii (the "radii") were monitored by dynamic light scattering. Thus, sodium acetate was added to the external buffer solution; when an antiporter is present, Na^+^ uptake coupled to H^+^ efflux creates an "inverted" ΔpH (alkali inside) that drives the uptake of neutral acetic acid and the net uptake of sodium acetate, driving water uptake and swelling.

Deactive *Bt*SMPs were placed into 250 m[m]{.smallcaps} sucrose and 10 m[m]{.smallcaps} Tris-SO~4~, pH 7.5, and their average radius was measured to be 145 ± 3 nm. When 250 m[m]{.smallcaps} sodium acetate was added to the external buffer (at constant sucrose and buffer concentrations), the radius increased significantly to 190 ± 15 nm; measurements were taken over 10 min from the addition of the sodium acetate (as the *Bt*SMPs continue to swell until they burst). In equivalent experiments with active *Bt*SMPs or with lithium acetate or potassium acetate, no significant changes in radius were observed (the variation was \<5 nm). The results are consistent with Na^+^/H^+^ exchange by deactive complex I only. However, experiments to test the effects of rotenone were unsuccessful because rotenone alone caused a significant (20 ± 5 nm) increase in the radius of both deactive and active *Bt*SMPs.

DISCUSSION
==========

### 

#### Monitoring Redox-driven Ion Translocation by Complex I

In our initial experiments, we used the ΔpH-sensitive dye ACMA to reconfirm that mitochondrial complex I catalyzes redox-linked H^+^ translocation, and a thermodynamic balance experiment to exclude the possibility of additional redox-linked Na^+^ translocation. To monitor H^+^ and Na^+^ transfer directly, in real time, we investigated several pH- and Na^+^-sensitive dyes, but were unable to identify any that did not inhibit catalysis and that could be incorporated into the lumenal volumes of coupled vesicles (see [supplemental Information](http://www.jbc.org/cgi/content/full/M112.384560/DC1)). Thus, to monitor Na^+^/H^+^ exchange, we designed experiments that relied upon the formation or dissipation of ΔpH monitored by using ACMA. ACMA was compatible with both PLs and SMPs, but its response is only semiquantitative; its fluorescence is affected by many molecules used here (notably DQ, ethanol, and M^+^ (where M^+^ = Li^+^, Na^+^, K^+^, or Rb^+^)), the level of quenching observed is subject to the size and concentration of the vesicles, the enzyme activity/concentration, and the lipid composition, and equal ΔpH values created differently (using different pH buffers, different NaCl concentrations with monensin or valinomycin + carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone) (FCCP) give different responses. Therefore, we compared only "like-with-like," employed exhaustive sets of controls, and supported our conclusions by vesicle-swelling experiments, a completely different measure of ion transport. We note that Na^+^ translocation by several prokaryotic complexes I has been studied previously by using radioactive ^22^Na, atomic absorption spectroscopy, or ^23^Na NMR with a shift reagent in the external solution to follow Na^+^ uptake into vesicles directly ([@B6]--[@B9]). However, these are not real-time methods (so short-lived ion gradients established during catalysis may relax before the measurement). Furthermore, the conclusions of studies of redox-driven ion translocation by *E. coli* complex I using these methods have disagreed completely; they have proposed that Na^+^ transfer occurs in opposite directions ([@B7], [@B9]).

#### The Na^+^/H^+^ Antiporter Activity of Deactive B. taurus Complex I

Our results show that deactive *Bt*CI is a Na^+^/H^+^ antiporter; it exchanges Na^+^ and H^+^ across a membrane to balance the ion- and proton-motive forces. Importantly, Na^+^/H^+^ exchange is independent of energy transduction; it halts when the enzyme is reactivated by redox-linked H^+^ translocation. Together with the sequence similarity of the complex I ND2, ND4, and ND5 subunits with the Mrp antiporter subunits MrpA and MrpD (see [supplemental Fig. 1](http://www.jbc.org/cgi/content/full/M112.384560/DC1) and [Fig. 1](#F1){ref-type="fig"}*B*), the ability of the complex I ND2, ND4, and ND5 subunits to rescue Mrp antiporter subunit knockouts in *Bacillus subtilis* ([@B3], [@B4]), and the Na^+^/H^+^ antiporter activity of an overexpressed truncated form of ND5 ([@B27]), our results suggest that one or more of ND2, ND4, and ND5 retain an inherent antiporter capability that is exhibited in the deactive enzyme. We propose that in deactive *Bt*CI, the functional connection between the redox and antiporter modules ([Fig. 1](#F1){ref-type="fig"}) is broken; energy-transducing catalysis abolishes the antiporter activity by initiating their reconnection, whereupon the redox domain "harnesses" the antiporter domain for proton translocation. It is further possible that the H^+^ transfer-ready states created by the redox reaction and by Na^+^ transfer resemble one another. Interestingly, rotenone binds more strongly to active *Bt*CI than to the deactive enzyme, and it partially prevents and reverses deactivation ([@B48]). Thus, rotenone does not inhibit the antiporter activity of deactive complex I directly; it abolishes it by functionally reconnecting the antiporter domain to the redox domain. The antiporter domain is brought under control and can no longer freewheel. Our proposal is consistent with the location of the rotenone-binding site in complex I, at the base of the redox domain, not in the antiporter-like subunits ([@B49]).

Antiporter activity was observed here only in deactive *Bt*CI, and not in *Yl*CI, despite the fact that the ND3 cysteine in "as prepared" *Yl*CI could be derivatized by NEM, a key diagnostic criterion for the deactive enzyme. Derivatizing the ND3 cysteine with NEM in *Bt*CI inhibits the antiporter activity, further confirming the link between the active/deactive status of the enzyme and the antiporter activity. Clear differences between the active/deactive transitions in *Bt*CI and *Yl*CI have been noted previously; for example, the apparent active/deactive transition is much less temperature-dependent in *Yl*CI ([@B50]). Thus, we propose that the deactive and active states in *Bt*CI differ more extensively than they do in *Yl*CI, with only the transition in *Bt*CI progressing to the functional disconnection of the redox and transport domains. It is possible that the truncation of ND2 in *Bt*CI ([Fig. 1](#F1){ref-type="fig"}*A*) is one determinant of the extent of the transition ([@B51]); the widely conserved cysteine in ND3 that is accessible to NEM only in the deactive enzyme is in a loop close to the three (truncated) helices ([@B2], [@B22]). Finally, we note that increased ACMA quenching was observed during catalysis by *E. coli* complex I PLs upon the addition of either extra NaCl or ETH-157, a sodium ionophore (although no antiporter activity was observed in an experiment similar to that shown in [Fig. 4](#F4){ref-type="fig"}) ([@B10]). This result was used to suggest "secondary antiporter activity," but no readily permeant ion was present, so it may arise from enhanced ion transfer that relaxes Δψ and facilitates ΔpH formation instead.

#### A Physiological Role for the Antiporter Activity of Deactive Complex I?

The deactive transition of complex I may contribute to determining the outcome of ischemia-reperfusion. Partially inhibiting the respiratory chain during ischemia, for example by inhibiting complex I, protects against mitochondrial damage and myocardial injury ([@B52]). Decreased respiratory chain turnover also favors the deactivation of complex I, making it susceptible to thiol reagents, such as *S*-nitrosothiols, that "lock" it in the deactive state ([@B14]) until the thiol pools recover. Thus, mitochondrially targeted *S*-nitrosothiols protect against ischemia-reperfusion injury ([@B53]). Our observation that deactive complex I is a Na^+^/H^+^ antiporter suggests an additional role for it during ischemia-reperfusion. Under normal conditions, transport cycles in the mitochondrial inner membrane, comprising Na^+^/H^+^ exchange, Na^+^/Ca^2+^ exchange, and Ca^2+^ uniport, contribute to cellular Ca^2+^ homeostasis ([@B54]). During ischemia, the intracellular Ca^2+^, Na^+^, and H^+^ concentrations rise, and Ca^2+^ accumulates in the mitochondrial matrix, contributing to opening the permeability transition pore ([@B54], [@B55]). It is possible that Na^+^/H^+^ exchange by deactive complex I influences Ca^2+^ accumulation by altering the ion transport properties of the inner membrane. Furthermore, Na^+^/H^+^ exchange across the inner membrane of mammalian mitochondria was identified more than 40 years ago by mitochondria-swelling experiments ([@B45]--[@B47]), but the protein responsible has not been identified ([@B56]). In our experiments, complex I is the dominant Na^+^/H^+^ exchanger, and a clear preference for Na^+^ over K^+^ was also observed in nonenergized mitochondria, consistent with a significant contribution from deactive complex I under these conditions. Finally, inhibiting Na^+^/H^+^ exchange across the plasma cell membrane, to attenuate the rise in intracellular Na^+^, is a well developed strategy for limiting ischemia-reperfusion injury ([@B55]). EIPA is one of the 5-*N*-substituted amiloride family of Na^+^/H^+^ exchange inhibitors, and ranolazine, in clinical use for angina, is proposed to be a Na^+^/H^+^ exchange inhibitor and also a complex I inhibitor ([@B33]). Here, we found no evidence that either compound inhibits Na^+^/H^+^ exchange by deactive complex I (although EIPA is an efficient uncoupler of Δ*p*). Thus, the response of deactive complex I to pharmacological agents is clearly distinct from that of the plasma membrane exchangers, inviting the prospect of targeting them individually.
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